Business & Finance
Veloxis Pharmaceuticals reports on share capital increase
24 August 2018 -

Veloxis Pharmaceuticals A/S (CPH:VELO), a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients, reported on Thursday an increase in the company's capital by 200,000 new shares with a nominal value of DKK0.10 each, corresponding to nominally DKK20,000, as a consequence of the exercise of warrants by former employees of the company granted under the company's warrant programme.

As a result of the employee's investment in the company, proceeds to Veloxis Pharmaceuticals from the capital increase amounts to DKK 70,000.

Reportedly, the subscription price for the new shares is DKK0.35 per share of nominal DKK0.10. These new shares will be listed on Nasdaq Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK171,283,853.10, divided into shares of DKK0.10 each.

Also, each share of nominal DKK0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S. The new shares give rights to dividend and other rights from the time of registration of the capital increase with the Danish Business Authority.